search

Omez

Overview Knowledge Hub

  • References: 

    1. Arora G, Singh G, Triadafilopoulos G. Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clin Gastroenterol Hepatol 2009;7(7):725–735.
    2. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of Omeprazole for the Treatment of Symptomatic Acid Reflux Disease Without Esophagitis. Arch Intern Med 2000;160:1810-1816. 
    3. Young A, Kumar MA, Thota PN. GERD: A practical approach. Cleve Clin J Med 2020;87:223-230. 
    4. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-726. 
    5. Based on internal analysis by Dr. Reddy’s Laboratories Ltd. using sales data from the following source: IQVIA MIDAS® Quarterly for the period MAT Sep 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

     

     s4 thumbnail  OMEZ 10. Reg.No.: 34/11.4.3/0299. Each capsule contains omeprazole 10 mg. Contains sugar (mannitol). 


    s4 thumbnail  OMEZ 20. Reg.No.: 34/11.4.3/0300. Each capsule contains omeprazole 20 mg. Contains sugar (mannitol). 


    s4 thumbnail  OMEZ 40. Reg.No.: 34/11.4.3/0301. Each capsule contains omeprazole 40 mg. Contains sugar (mannitol).

     

    For full prescribing information please refer to the professional information approved by the Medicines Regulatory Authority. 
    Dr. Reddy’s Laboratories (Pty) Ltd., 204 Rivonia Road, Block B, Morningside, Sandton, 2057. Reg.No.: 2002/014163/07. Tel: +27 11 324 2100. www.drreddys.co.za. 
    This content is for Healthcare Professionals only. The intended recipient should not share or forward it. 

    Click here to access product and company information
    OmezHeroBanner2

  • References: 

    1. Arora G, Singh G, Triadafilopoulos G. Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clin Gastroenterol Hepatol 2009;7(7):725–735.
    2. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of Omeprazole for the Treatment of Symptomatic Acid Reflux Disease Without Esophagitis. Arch Intern Med 2000;160:1810-1816. 
    3. Young A, Kumar MA, Thota PN. GERD: A practical approach. Cleve Clin J Med 2020;87:223-230. 
    4. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-726. 
    5. Based on internal analysis by Dr. Reddy’s Laboratories Ltd. using sales data from the following source: IQVIA MIDAS® Quarterly for the period MAT Sep 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

     

     s4 thumbnail  OMEZ 10. Reg.No.: 34/11.4.3/0299. Each capsule contains omeprazole 10 mg. Contains sugar (mannitol). 


    s4 thumbnail  OMEZ 20. Reg.No.: 34/11.4.3/0300. Each capsule contains omeprazole 20 mg. Contains sugar (mannitol). 


    s4 thumbnail  OMEZ 40. Reg.No.: 34/11.4.3/0301. Each capsule contains omeprazole 40 mg. Contains sugar (mannitol).

     

    For full prescribing information please refer to the professional information approved by the Medicines Regulatory Authority. 
    Dr. Reddy’s Laboratories (Pty) Ltd., 204 Rivonia Road, Block B, Morningside, Sandton, 2057. Reg.No.: 2002/014163/07. Tel: +27 11 324 2100. www.drreddys.co.za. 
    This content is for Healthcare Professionals only. The intended recipient should not share or forward it. 

    Click here to access product and company information
    OmezHeroBanner3

  • References: 

    1. Arora G, Singh G, Triadafilopoulos G. Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice. Clin Gastroenterol Hepatol 2009;7(7):725–735.
    2. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of Omeprazole for the Treatment of Symptomatic Acid Reflux Disease Without Esophagitis. Arch Intern Med 2000;160:1810-1816. 
    3. Young A, Kumar MA, Thota PN. GERD: A practical approach. Cleve Clin J Med 2020;87:223-230. 
    4. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-726. 
    5. Based on internal analysis by Dr. Reddy’s Laboratories Ltd. using sales data from the following source: IQVIA MIDAS® Quarterly for the period MAT Sep 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

     

     Image removed.  OMEZ 10. Reg.No.: 34/11.4.3/0299. Each capsule contains omeprazole 10 mg. Contains sugar (mannitol). 


    Image removed.  OMEZ 20. Reg.No.: 34/11.4.3/0300. Each capsule contains omeprazole 20 mg. Contains sugar (mannitol). 


    Image removed.  OMEZ 40. Reg.No.: 34/11.4.3/0301. Each capsule contains omeprazole 40 mg. Contains sugar (mannitol).

     

    For full prescribing information please refer to the professional information approved by the Medicines Regulatory Authority. 
    Dr. Reddy’s Laboratories (Pty) Ltd., 204 Rivonia Road, Block B, Morningside, Sandton, 2057. Reg.No.: 2002/014163/07. Tel: +27 11 324 2100. www.drreddys.co.za. 
    This content is for Healthcare Professionals only. The intended recipient should not share or forward it. 

    Click here to access product and company information
    OmezHeroBanner1

Overview

  • Omeprazole was the first proton pump inhibitor discovered in 1979, and it has revolutionized the management of numerous gastrointestinal diseases.
  • Omeprazole is a well-established and most-studied drug in the PPI class.

About Brand (PI content)

Pharmacological classification

  • Medicines acting on the gastrointestinal tract – Other Omeprazole is an inhibitor of the gastric proton pump (H+, K+-ATPase). It inhibits both basal and stimulated gastric acid secretion by parietal cells, whether induced by acetylcholine, gastrin, or histamine. 

  • Omeprazole does not affect acetylcholine, histamine, or gastrin receptors.

Mechanism of action

  • Omeprazole is an inhibitor of the gastric proton pump (H+, K+-ATPase). It inhibits both basal and stimulated gastric acid secretion by parietal cells, whether induced by acetylcholine, gastrin, or histamine.

  • Omeprazole does not affect acetylcholine, histamine, or gastrin receptors.

Strengths

  • 10 mg capsule, 20 mg capsule, 40 mg capsule

Pack size 

  • OMEZ 10 white HDPE bottles containing 30 capsules.

  • OMEZ 20 white HDPE bottles containing 30 capsules.

  • OMEZ 40 white HDPE bottles containing 30 capsules.

Indications

Adults: 

  • Duodenal ulcer, including prevention of relapse

  • Gastric ulcer, and reflux oesophagitis

  • Long-term management of reflux oesophagitis and Zollinger-Ellison Syndrome

  • Symptomatic relief of heartburn in patients with gastro-oesophageal reflux disease and the short-term relief of functional dyspepsia

  • Helicobacter pylori-positive duodenal ulcers as part of an eradication program with appropriate antibiotics

  • Treatment of non-steroidal anti-inflammatory drugs -associated gastric and/or duodenal ulcer/erosions

  • Reduction of the risk of developing gastric and/or duodenal ulcer/erosions

  • Reduction of the risk of relapse for previously healed gastric and/or duodenal ulcer/erosions in patients on NSAID treatment.

Children:

  • Short-term (up to 3 months) treatment of severe ulcerative reflux oesophagitis resistant to previous medical treatment.

Dosage

  • Duodenal ulcer 
    20 mg once daily for two to four weeks. In some duodenal ulcer patient's refractory to other treatment regimens, 40 mg once daily may be effective.     

  • Prevention of relapse in patients with duodenal ulcer
    10 mg once daily. If necessary, the dose can be increased to 20 to 40 mg once daily. The above-recommended dosage regimens are inclusive of Helicobacter pylori-positive duodenal ulcers as part of the eradication programme with appropriate antibiotics.     

  • Gastric ulcer and reflux oesophagitis 
    20 mg once daily for four to eight weeks. In some gastric ulcer and reflux oesophagitis patient's refractory to other treatment regimens, 40 mg once daily may be effective. For the long-term management of patients with reflux oesophagitis the recommended dose is 20 mg once daily. If necessary, the dose can be increased to 20 to 40 mg once daily. In patients with severe or symptomatic recurrent reflux oesophagitis treatment can be continued with OMEZ at a dosage of 20 mg once daily.     

  • NSAID-associated gastro-duodenal lesions with or without continued NSAID treatment 
    20 mg once daily.  In most patients, healing occurs within 4 weeks. For patients who may not be fully healed after the initial course healing usually occurs during a further 4 weeks of treatment. 

  • Prevention of NSAID-associated gastro-duodenal lesions and dyspeptic symptoms 
    20 mg once daily. 

  • Symptomatic gastro-oesophageal reflux disease 
    20 mg daily. Patients may respond adequately to 10 mg daily; therefore, individual dose adjustments should be considered. If symptom control has not been achieved after four weeks of treatment with the prescribed daily dose further investigation is recommended. 

Dosage

  • Zollinger-Ellison Syndrome 
    60 mg once daily. The dosage should be adjusted individually, and treatment continued as long as it is clinically indicated. With doses above 80 mg daily, the dose should be divided and given twice daily. There is very limited experience with the use of OMEZ in children.     

  • Severe ulcerative reflux oesophagitis in children from one year and older 

Recommended dosages: 

image


*For further information on contra-indications, side-effects, special warning, and storage instructions, please refer to the professional information by clicking below.

Knowledge Hub